[Form 4] Akoya BioSciences, Inc. Insider Trading Activity
Filing Impact
Filing Sentiment
Form Type
4
Insider Trade Summary
10 transactions reported
Mixed
10 txns
Insider
McKelligon Brian
Role
President and CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Other | Employee Stock Option (Right to Buy) | 393,338 | $0.00 | -- |
| Other | Employee Stock Option (Right to Buy) | 331,090 | $0.00 | -- |
| Other | Employee Stock Option (Right to Buy) | 241,592 | $0.00 | -- |
| Other | Employee Stock Option (Right to Buy) | 160,000 | $0.00 | -- |
| Other | Employee Stock Option (Right to Buy) | 160,000 | $0.00 | -- |
| Other | Employee Stock Option (Right to Buy) | 175,000 | $0.00 | -- |
| Other | Common Stock | 393,338 | $0.00 | -- |
| Other | Common Stock | 331,090 | $0.00 | -- |
| Tax Withholding | Common Stock | 196,866 | $0.00 | -- |
| Other | Common Stock | 947,688 | $0.00 | -- |
Holdings After Transaction:
Employee Stock Option (Right to Buy) — 0 shares (Direct);
Common Stock — 813,464 shares (Direct)
Footnotes (1)
- Cashless exercise of options pursuant to that certain Amended and Restated Agreement and Plan of Merger dated as of April 28, 2025, as amended (the "Merger Agreement"), by and among Quanterix Corporation, a Delaware corporation ("Quanterix"), Wellfleet Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Quanterix ("Merger Sub"), and the Issuer. On July 8, 2025 (the "Closing Date"), Merger Sub merged with and into Issuer (the "Merger"), with Issuer surviving the Merger as a wholly owned subsidiary of Quanterix. Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price less than the value of the Per Share Merger Consideration (as defined below) was automatically cashless exercised. Disposition of shares pursuant to Merger Agreement. In connection with the terms of the Merger Agreement, each share of common stock of Issuer outstanding on the Closing Date was converted into the right to receive (a) 0.1461 of a share of common stock of Quanterix (the "Per Share Stock Consideration") and (b) $0.38 in cash, without interest (the "Per Share Cash Consideration" and together with the Per Share Stock Consideration, the "Per Share Merger Consideration"). Each of the Per Share Stock Consideration and the Per Share Cash Consideration may be adjusted pursuant to the terms of the Merger Agreement. Disposition of options pursuant to the Merger Agreement. Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration.
